Protara Therapeutics is trading at $3.35, down 5.5%, with the decline appearing tied to broader biotech and risk-off pressure.
- No new company-specific announcement emerged on September 24, 2026. The latest investor-relations release located was dated September 8 and concerned a future conference presentation.
- XBI is down 2.04%, and major indexes are lower as the 10-year Treasury yield reaches roughly 5.14%, weighing particularly heavily on growth-oriented biotechnology stocks.